Funding Needs and Financing Risk Associated with Research and Development and Capital Investment
First written in FY2017. 13 of 16 entries say "Mitigated", first in FY2018. Latest entry: FY2026.
The whole theme swung hardest in 2025: 16 of 29 companies on the "Worse" side.
15 other companies' latest entry also says "Worsened".
- FY2026WorsenedAnnual report
「Funding needs for working capital, research and development investment, capital investment and other purposes are expected to increase as the business progresses. The company will continue to strengthen its financial base by diversifying its financing methods, including raising funds from the stock market and using government subsidies and other public assistance. However, depending on its ability to secure earnings and the status of financing, the group's operating results and financial condition may be affected.」
The company expects funding needs for working capital, research and development investment and capital investment to increase, and has reaffirmed the financing risk associated with continuing to raise funds through equity financing and the use of public subsidies. - FY2024-Q3MitigatedAnnual report
「The funds expected to be raised through the issuance and exercise of the Series 16 Stock Acquisition Rights will be allocated to working capital from January 2024 onward. Of the ¥1,990 million that could not be raised previously, the company plans once again to allocate funds to the introduction of new pipelines and clinical trial expenses.」
The company has presented a plan to raise additional funds through the 16th Series of Stock Acquisition Rights to cover the funding shortfall under the 15th Series, thereby specifying a financing method for research and development, clinical trials and other funding needs. - FY2023MitigatedAnnual report
「The group's basic policy is to secure a stable supply of the liquidity and funds necessary for business operations. However, because operating income is insufficient to cover these funding needs, the group is using public grants and funds raised through a third-party allotment. As of the end of the consolidated fiscal year, the group had ¥1,914 million in cash and deposits and ¥4,464 million in securities held for short-term investment, ensuring sufficient liquidity.」
The company explained that it is using public grants, a third-party allotment, the exercise of stock acquisition rights and available liquidity to meet funding needs for research and development, clinical trials and other activities. In FY2023, it raised ¥562 million through the exercise of stock acquisition rights. - FY2023-Q2MitigatedAnnual report
「Funds obtained from financing activities during the six-month period of the current consolidated fiscal year amounted to ¥484 million, compared with ¥686 million in the same period of the previous year. This was mainly due to proceeds of ¥564 million from the issuance of shares through the exercise of stock acquisition rights.」
The company raised ¥564 million through the exercise of stock acquisition rights to meet funding needs for research and development, clinical trials and other activities. However, additional financing through the remaining stock acquisition rights was discontinued. - FY2023-Q1MitigatedAnnual report
「Funds raised through the exercise of rights during the quarter (¥ millions) 204」
The company raised ¥204 million through the exercise of stock acquisition rights to meet funding needs for research and development, clinical trials and other activities, and continues to raise funds. - FY2022-Q3MitigatedAnnual report
「Through the issuance of new shares upon the exercise of stock acquisition rights, the company increased both its share capital and capital surplus by ¥1,113.106 million during the nine-month period of the current consolidated fiscal year.」
To meet funding needs for research and development, clinical trials and other activities, the exercise of stock acquisition rights increased both share capital and capital surplus by ¥1,113 million, advancing equity financing. - FY2022-Q2MitigatedAnnual report
「Funds generated from financing activities during the first six months of the current consolidated fiscal year amounted to ¥686 million (¥2 million in the same period of the previous year). This was mainly attributable to ¥668 million in proceeds from the issuance of shares through exercise of the Stock Acquisition Rights.」
The company raised ¥668 million through the exercise of stock acquisition rights to meet funding needs for research and development, clinical trials and other activities, and continues to raise funds. - FY2021MitigatedAnnual report
「The company is using public grants and funds raised through a third-party allotment. As of the end of the consolidated fiscal year, the group had ¥2,601 million in cash and deposits and ¥2,000 million in securities held for short-term investment, ensuring sufficient liquidity.」
The company has reaffirmed its approach of using public grants, a third-party allotment and available liquidity to meet funding needs for research and development, clinical trials and capital investment. - FY2021-Q1RestatedAnnual report
「At the end of the first quarter of the current consolidated fiscal year, the group had ¥4,955 million in cash and deposits, and its financial base was stable.」
Amid the front-loading of research and development and clinical trial expenses, the company reaffirmed the stability of its financial base, supported by ¥4,955 million in cash on hand. - FY2020MitigatedAnnual report
「The company is using public grants and funds raised through a third-party allotment. As of the end of the consolidated fiscal year, the group had ¥4,585 million in cash and deposits and ¥600 million in securities held for short-term investment, ensuring sufficient liquidity.」
The company explained that it is using public grants, a third-party allotment and available liquidity to meet funding needs for research and development and capital investment. - FY2019-Q2MitigatedAnnual report
「During the first six months of the current consolidated fiscal year, the company issued the Series 14 Stock Acquisition Rights, with EVO FUND as the allottee, primarily to fund development expenses for iPS cell-derived neural glial cells (iGRP), a regenerative medicine product. The rights were fully exercised in August, raising ¥1,383 million.」
The company secured funding for research and development and clinical trial needs through the completion of the exercise of the 14th Series of Stock Acquisition Rights, raising ¥1,383 million. - FY2019-Q1MitigatedAnnual report
「The company plans to raise approximately ¥2 billion through the issuance of these stock acquisition rights.」
The company resolved to issue the 14th Series of Stock Acquisition Rights to fund the development costs of iGRP, thereby specifying a financing method for funding needs related to research and development, clinical trials and other activities. - FY2018MitigatedAnnual report
「The company will continue to strengthen its financial base by diversifying its financing methods, including raising funds from the stock market and using government subsidies and other public assistance.」
The company is diversifying its financing methods, including the exercise of stock acquisition rights, public grants and additional issuances of stock acquisition rights, in response to funding needs associated with ongoing research and development and capital investment. - FY2017First statedAnnual report
「The company will continue to strengthen its financial base by diversifying its financing methods, including raising funds from the stock market and using government subsidies and other public assistance. However, depending on its ability to secure earnings and the status of financing, the group's operating results and financial condition may be affected.」
The company disclosed its dependence on the stock market and public subsidies for funding needs associated with research and development, clinical trials and capital investment, as well as the risks related to financing conditions.